Purpose: To compare the 1-year outcomes of treat-and-extend (TAE) and every-other-month (2M) regimens with intravitreal aflibercept in Japanese wet age-related macular degeneration (AMD) patients. Methods: Prospective, multicenter, randomized clinical trial. The primary outcome measure was the proportion of eyes in which the best-corrected visual acuity (BCVA) was maintained at week 52 [with a loss of <0.3 logarithm of minimum angular of resolution (logMAR) units]. The secondary outcome measures were the mean change from baseline in the central retinal thickness (CRT) and the number of injections. Results: Forty-one patients were enrolled. The mean changes in the BCVA from baseline in the TAE and 2M were À0.32 AE 0.27 and À0.26 AE 0.30 logMAR units (p = 0.46). The TAE group was noninferior to the 2M group in BCVA maintenance. The mean CRT changes from baseline in the TAE and 2M were À161 AE 133 and À157 AE 90 lm (p = 0.73). The mean number of injections in the TAE and 2M were 7.5 AE 1.2 (range, 7-12) and 8.0 AE 0.0 (p < 0.0001). Conclusion: Treat-and-extend (TAE) regimen with aflibercept improved the BCVA and CRT to the same extent as 2M regimen, with a reduced number of injections.
Introduction
Age-related macular degeneration (AMD) is the leading cause of vision loss among individuals of ≥50 years of age (Congdon et al. 2004) . Wet-AMD is characterized by choroidal neovascularization (CNV) (Chopdar et al. 2003) . The proliferation of CNV is stimulated by vascular endothelial growth factor (VEGF) (Kliffen et al. 1997; Adamis & Shima 2005) . Currently, wet-AMD is most commonly treated with anti-VEGF drugs. Aflibercept is a relatively new drug for the treatment of wet-AMD (Stewart 2012) . In the VEGF Trap-Eye Investigation of Efficacy and Safety in Wet-AMD (VIEW 1 and VIEW 2), intravitreal injections of aflibercept every-othermonth after three initial monthly injections were found to be safe and noninferior in comparison with the monthly intravitreal injection of ranibizumab over a 1-year period (Heier et al. 2012) .
In an attempt to prolong the period between injections, a TAE regimen was suggested (Brown & Regillo 2007; Spaide 2007 Spaide , 2009 ). The treatment interval was sequentially lengthened by 1-2 weeks as long as there were no signs of recurrent exudation. When recurrent exudation was detected on a follow-up visit, the treatment interval was reduced to the prior interval. The time between visits was individualized based on the response to treatment. The TAE regimen attempts to maintain an exudation-free macula while reducing the number of intravitreal injections, office visits and examinations.
To date, various outcomes of TAE regimens with bevacizumab or ranibizumab have been reported (Toalster et al. 2013; Abedi et al. 2014; Wykoff et al. 2015; Berg et al. 2016) ; however, there have been few retrospective reports in relation to aflibercept (Matsumoto et al. 2016; Ohnaka et al. 2016; Barthelmes et al. 2017) . Moreover, the therapeutic outcomes have been compared to those of a fixed dosing regimen with ranibizumab (Wykoff et al. 2015) , but not with aflibercept. The purpose of this study is to compare the outcomes of TAE and fixed dosing regimens with aflibercept in Japanese wet-AMD patients after at least 1 year of follow-up.
Patients and Methods

Study design
A prospective, multicenter, randomized clinical trial
In this study, the inclusion criteria were the patients who had active, subfoveal CNV lesions (or juxtafoveal lesions with leakage affecting the fovea) secondary to neovascular AMD in the study eye and were ≥50 years of age. This study was registered in UMIN (University Hospital Medical Information Network, UMIN ID: 000014946) before the enrolment of the first patient. All of the research was performed in accordance with the tenets of Declaration of Helsinki and was approved by the Institutional Review Board of Kumamoto University and the Review Board of Ideta Eye Hospital. All of the patients provided their written informed consent before undergoing treatment. This study was performed at Kumamoto University Hospital and Ideta Eye Hospital between 1 August 2014 and 31 October 2016.
The patients were randomized into a TAE and 2M groups. All of the patients underwent a baseline examination that included the BCVA with Landolt C charts, dilated fundoscopy and colour fundus photography. The decimal BCVA was converted to logMAR units, Snellen visual acuity fractions and approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores (Gregori et al. 2010) . Spectral domain optical coherence tomography (SD-OCT), fluorescein angiography (FA) and indocyanine green angiography (ICGA) were examined using Spectralis HRA + OCT (Heidelberg Engineering, Heidelberg, Germany) at Kumamoto University Hospital. Spectral domain optical coherence tomography (SD-OCT) was performed using Cirrus OCT (Carl Zeiss Meditec, Jena, Germany), and FA and ICGA were performed using VX-10i (Kowa Company, Nagoya, Japan) at Ideta Eye Hospital. Spectral domain optical coherence tomography (SD-OCT) was performed to determine the presence or absence of intraretinal fluid and subretinal fluid, and to assess the CRT. Horizontal and vertical scans were performed through the foveal centre in all patients, and additional scans were performed as necessary. The follow-up examination intervals were determined according to the TAE or 2M protocols. After the three initial monthly intravitreal injections of aflibercept (IVA; 2.0 mg), the TAE group was examined at 4 weeks after the third injection. If the disease state was considered to be 'active' [the BCVA had declined by 0.1 logMAR units, or if there was any clinical or OCT evidence of disease activity (haemorrhage, intraretinal fluid or subretinal fluid)], the patients received IVA for 6 weeks after the third injection. If the disease state was 'inactive', then IVA was administered for 8 weeks after the third injection. If the disease state remained 'inactive', the retreatment interval was increased by 2 weeks until a 12-week interval was established. The intervals were not extended beyond 12 weeks. If the disease state was considered 'active', the interval between injections was decreased by 2 weeks. The minimum interval was 4 weeks. The patients received IVA at the same time as the scheduled date in the follow-up examination. On the other hand, in the 2M group, IVA was performed every 2 months after the three initial monthly injections. In all patients, the BCVA was examined, and dilated fundoscopy, colour fundus photography and OCT were performed each time they visited for an injection, and at 12, 24, 36 and 52 weeks after the first injection. Fluorescein angiography (FA) and ICGA were not performed in follow-up examinations.
The primary outcome measure in this study was the proportion of eyes in which the BCVA was maintained at within 0.3 logMAR units from the baseline at week 52. The secondary outcome measures were the mean change in CRT at week 52, and the number of IVA at week 52.
The data were analysed using frequency and descriptive statistics. The data are presented as the mean AE standard deviation. The statistical analyses included the Fisher's exact test for the contingency table, the Welch's t-test for independent samples, the paired t-test for paired samples, the Mann-Whitney U-test for nonparametric samples and the Farrington and Manning test for noninferiority analysis. A noninferiority margin of 15% was chosen to preserve approximately two-third of aflibercept effect for maintenance BCVA demonstrated in VIEW studies using the two confidence interval approaches (Heier et al. 2012 (Kanda 2013) . In the VIEW studies, 95% of patients who received IVA with 2M injections of aflibercept after three initial monthly injections maintained BCVA at 1 year (Heier et al. 2012 ). On the other hand, it was reported that 95%-98% of patients who received ranibizumab or bevacizumab with TAE regimen maintained BCVA at 1 year (Toalster et al. 2013; Abedi et al. 2014) . Assuming the proportions of patients who maintained BCVA at week 52 in the 2M and TAE groups to be 95% and 96.5%, respectively, a sample size of 19 patients per group was estimated to provide 80% power, 15% noninferiority margin and 5% significance for a chi-squared test of noninferiority for a 2 9 2 contingency table for the comparison of the 2M and TAE regimens for the primary end-point. The EZR software program (version: 1.33) was used to calculate the sample size (Kanda 2013) .
Results
Baseline clinical characteristics
A total of 41 patients (41 eyes) met the criteria for inclusion in this study. All e394 of the patients were Japanese. Their baseline characteristics are presented in Table 1 . No significant differences were found in the baseline values of the eyes treated with the TAE regimen and those treated with the 2M regimen (p > 0.165). Fig. 1 , the mean BCVA gains were similar between two groups. Mean BCVA gains improved 0.32 AE 0.27 (15.9) and 0.26 AE 0.30 (13.1) logMAR units (approximate ETDRS letters) in the TAE and 2M groups at week 52. There was no significant difference between the two groups in the mean change in the BCVA from baseline at weeks 12, 24, 36 or 52 (p = 0.395, 0.990, 0.676 and 0.463, Mann-Whitney U-test). By week 52, nine of 21 (43%) eyes showed an improved BCVA (change defined as ≤À0.3 log-MAR units), 12 (57%) eyes had no change, and no eyes had a decreased BCVA (change defined as ≥0.3 log-MAR units) in the TAE group. On the other hand, nine of 20 (45%) eyes had an improved BCVA, 11 (55%) eyes had no change; no eyes had a decreased BCVA by week 52 in the 2M group. At week 52, the BCVA was maintained in all of the eyes in the both groups. The TAE group was noninferior to the 2M group in the proportion of eyes in which the BCVA was maintained at week 52 [difference between the two groups: 0% (95% confidence interval = À12.8% to 12.8%), p = 0.027, Farrington and Manning test].
The central retinal thickness outcomes
The mean CRT in the TAE group decreased to 211 AE 36 lm at week 12 (p < 0.0001, paired t-test) and then to 213 AE 57 lm at week 52 (p < 0.0001). On the other hand, the mean CRT in the 2M group decreased to 209 AE 51 lm at week 12 (p < 0.0001) and then to 197 AE 50 lm at week 52 (p < 0.0001). As shown in Fig. 2 , the mean CRT improved 161 AE 133 lm and 157 AE 90 lm in the TAE and 2M groups at weeks 52. There was no significant difference between the groups in the change in the CRT at weeks 12, 24, 36 and 52 (p = 0.958, 0.876, 0.917 and 0.735, Mann-Whitney U-test).
Number of injections
The mean number of injections at week 52 in the TAE and 2M groups was 7.5 AE 1.2 and 8.0 AE 0.0, respectively (p < 0.0001, Mann-Whitney U-test). In the TAE group, 16 (76%) eyes received seven injections, three (14%) eyes received eight injections, one (4.8%) eye received nine injections and one (4.8%) eye received 12 injections. In the 2M group, all eyes received eight injections.
Discussion
In the present study, we investigated the clinical outcome of 1 year of aflibercept treatment with the TAE and 2M regimens in Japanese wet-AMD patients. There were no significant differences in the mean changes in the BCVA and CRT from baseline in the TAE and 2M groups. In all eyes of both groups, the BCVA was maintained at week 52, whereas the patients in the TAE group received fewer aflibercept injections than the 2M group. To the best of our knowledge, this is the first study to compare the results of aflibercept treatment with the TAE and 2M regimens prospectively.
In the breakthrough MARINA and ANCHOR trials, the improvements in the BCVA of wet-AMD patients who underwent 2 years of treatment with fixed monthly doses of ranibizumab were markedly greater than those in patients who received a sham injection (Rosenfeld et al. 2006) or photodynamic therapy (Brown et al. 2009 ). Despite the clinical improvements, it is practically difficult to maintain the therapeutic benefit due to the physical and economic burden associated with monthly dosing. Pro re nata (PRN) and TAE regimens are increasingly used in clinical practice to optimize the clinical improvement and economic cost. In the Comparison of AMD Treatment Trials (CATT), the administration of PRN regimen with ranibizumab had similar effects on the BCVA over 2 years to monthly dosing with ranibizumab (Martin et al. 2012 ). In the SEVEN-UP study, which assessed the long-term outcomes with ranibizumab PRN therapy after the MARINA and ANCHOR study, however, the BCVA at 7.3 years was found to have declined to 8.6 ETDRS letters worse than at baseline (Rofagha et al. 2013) . It was pointed that a lower frequency of treatment might have contributed to the BCVA decline observed in the SEVEN-UP study period. Without strict monthly monitoring visits, the PRN regimen was not effective for maintaining vision. Spaide proposed the TAE regimen, called the 'inject and extend' regimen, in 2007 to achieve and maintain a dry macula by gradually increasing the length of time between the injections in the absence of haemorrhage or signs of exudation (Spaide 2007) . In a recent study, a TAE regimen with ranibizumab was reported to achieve a favourable improvement in the BCVA and CRT of wet-AMD patients while reducing the number of injections (Wykoff et al. 2015) . Regarding the long-term effectiveness, the TAE regimen was reported to be effective in achieving and maintaining visual improvements in patients with wet-AMD for more than 2 years of treatment (Rayess et al. 2015; Barthelmes et al. 2017 ). In the 'inject and extend' regimen, patients receive injection for 6 weeks after three initial monthly injections followed by intervals increasing by 2 weeks until exudation recurs. Referring to the 'inject and extend' regimen, the fourth injection was administered 6 weeks after the third injection in the TAE group, even if the disease state was considered to be 'active' at 4 weeks after the third injection.
A mean gain of 16 and 13 ETDRS letters was achieved over 1 year in the TAE and 2M groups, respectively. The BCVA improved to a greater degree in the present study than in previous studies involving patients treated by ranibizumab or bevacizumab with the TAE regimen and VIEW studies (gain of 6.5-10.5 ETDRS letters) (Heier et al. 2012; Toalster et al. 2013; Abedi et al. 2014; Wykoff et al. 2015) . Possible reasons for this difference include the ceiling effect and the high prevalence of patients with PCV in the present study. The baseline BCVA influences the BCVA variation in response to treatment as well as the final BCVA, as has been demonstrated previously (Zhu et al. 2015; Pedrosa et al. 2016; Tomkins-Netzer et al. 2017) . Patients with a lower baseline BCVA tend to gain more letters than those with a higher baseline BCVA. However, the baseline BCVA in the present study was not markedly lower than that in previous studies with the TAE regimen (51-61 ETDRS letters) and VIEW studies (56 and 52 ETDRS letters) (Heier et al. 2012; Toalster et al. 2013; Abedi et al. 2014; Wykoff et al. 2015) .
The prevalence of PCV is 23%-55% in Japanese patients and 8%-10% in Caucasian patients with presumed wet-AMD (Yannuzzi et al. 1997; Scassellati-Sforzolini et al. 2001; Sho et al. 2003; Obata et al. 2006; Maruko et al. 2007 ). In the present study, 63% of patients had PCV. While some studies have found such patients to be refractory to anti-VEGF therapy (Cho et al. 2009; Stangos et al. 2010) , other recent studies have shown satisfactory effects of ranibizumab and aflibercept in patients with PCV. Indeed, a retrospective study reported a 14.8 ETDRS letters improvement in the BCVA in Japanese patients with PCV treated by aflibercept with a 2M regimen over 1 year among those who met the BCVA inclusion criteria of VIEW studies (Yamamoto et al. 2015) . Another retrospective study found a 17 ETDRS letters improvement in the BCVA from the baseline (53 ETDRS letters) in PCV patients in South Korea treated with ranibizumab TAE regimen over 1 year (Pak et al. 2017 ). These results suggest that eyes with PCV treated with anti-VEGF drugs may have higher BCVA gains than those with typical AMD. However, a prospective study reported that there was no statistically significant difference in the change in the BCVA over 1 year between PCV and typical AMD patients treated by aflibercept with a 2M regimen (Oishi et al. 2015) . Because few studies have conducted direct comparisons of the outcomes of anti-VEGF drugs for PCV and typical AMD patients, the differences in the clinical efficacy of anti-VEGF drugs between PCV and typical AMD patients are still unclear. Previous prospective studies showed that 25%-31% of eyes were improved (gain of ≥15 ETDRS letters) and 95%-98% of eyes were maintained (loss of <15 ETDRS letters) at 1 year in patients who received TAE regimen with ranibizumab or bevacizumab (Toalster et al. 2013; Abedi et al. 2014; Wykoff et al. 2015) . In retrospective studies of patients with PCV, 25% and 52% of eyes were improved, and 96% and 100% of eyes were maintained at 1 year in patients who received the 2M regimen with aflibercept and the TAE regimen with ranibizumab, respectively (Yamamoto et al. 2015; Pak et al. 2017) . The overall results for the patients in the present study are generally in line with those of previous studies in terms of the maintenance in 100% of patients who received the TAE and 2M regimens with aflibercept. In addition, an improvement in the BCVA was achieved in 43% and 45% of patients in the TAE and 2M groups.
The CRT is an objective measurement of the effects of anti-VEGF drugs on CNV activity. In this study, the CRT improvement over 1 year did not differ between the two groups to a statistically significant extent. This result was similar to the results of previous studies in which TAE regimens with ranibizumab or bevacizumab were administered (112-173 lm) (Wykoff et al. 2015; Berg et al. 2016) , and the VIEW studies in which 2M regimens with aflibercept were administered (129 and 149 lm) (Heier et al. 2012) .
The mean number of aflibercept injections over a 1-year period was 7.5 in the TAE group and 8.0 in the 2M group. This difference of 0.5 injections over the 1-year period was statistically significant but may be unimportant from a clinical standpoint for individual patients. However, the difference is important from a general medical economic standpoint, as aflibercept is an expensive drug, and the prevalence of AMD will continue to increase (Rein et al. 2009; Kume et al. 2016) . In previous studies of TAE regimens with ranibizumab or bevacizumab, a mean of 8.0-10.1 injections was administered (Toalster et al. 2013; Abedi et al. 2014; Rush et al. 2014; Wykoff et al. 2015; Berg et al. 2016) . Variations in protocols for TAE regimens have been noted. In most previous studies, monthly injections were performed until no fluid was observed, followed by intervals increasing by 2 weeks until exudation recurred. On the other hand, some studies have introduced loading doses (Freund et al. 2015) . In the present study, both groups received three initial monthly injections as the loading doses. The number of injections, therefore, may be higher than with TAE regimens with no loading doses. Furthermore, the TAE group was injected 2 weeks later for the fourth injection than previous TAE regimens with loading doses if the disease state was considered to be 'active' after the third injection (6 weeks in the present study, 4 weeks in the previous studies) (Rush et al. 2014; Wykoff et al. 2015) . In the present study, the disease state was 'active' in only one patient at 4 weeks after the third injection. However, this delay of fourth injection may contribute to the occurrence of a low number of injections in the relatively short follow-up period. Although the number of injections in the TAE group cannot directly be compared to those in other studies, aflibercept may require fewer injections and allow for longer treatment intervals than ranibizumab or bevacizumab when wet-AMD patients receive a TAE regimen. Because the high VEGFbinding affinity and the intra-ocular biological activity of aflibercept may contribute to the reduction in the number of injections (Stewart & Rosenfeld 2008) .
Several limitations associated with the present study warrant mention. First, there were differences in the baseline BCVA and type of AMD between the TAE and 2M groups. Although there were no statistically significant differences in these parameters, the mean baseline BCVA in the 2M group was 6 ETDRS letters better than that in the TAE group. The ceiling effect may contribute to the differences in the gain of BCVA at week 52 (TAE, 16; 2M, 13 ETDRS letters). Second, there was a high prevalence of PCV patients. The prevalence of PCV in Japanese wet-AMD patients is higher than that in Caucasian patients. Therefore, the results in the present study may not be able to be extrapolated to Caucasian patients. Third, the proportion of eyes with maintained vision was determined for the primary outcome measure. A similar rate for maintained vision was reported for ranibizumab or aflibercept with TAE or fixed regimen at 1 year (Rosenfeld et al. 2006; Heier et al. 2012; Toalster et al. 2013; Barthelmes et al. 2017) . Indeed, all patients demonstrated maintained vision in the present study. Another method might be needed to evaluate the BCVA between the TAE and 2M regimens. Finally, this study had a small sample size and a short followup period. A subtype analysis was not conducted because of the small number of patients. The differences in the effect of the TAE regimen with aflibercept among subtypes of AMD remain unclear. The higher gain in the BCVA in the present study might be due to the small sample size. In addition, a 1-year follow-up period may not be long enough to assess the results of treatment adequately, as patients require lifelong disease management with anti-VEGF treatment. A larger population and longer follow-up period will be needed to confirm the usefulness of TAE regimens with aflibercept.
In conclusion, our study investigated the clinical outcomes over 1 year in Japanese wet-AMD patients who received either a TAE regimen or a 2M regimen with aflibercept. Both regimens achieved similarly good visual and anatomical outcomes over 1 year of treatment. However, the patients in the TAE group received fewer injections than those in the 2M group. Thus, a TAE regimen with aflibercept can offer good results with fewer injections than the 2M regimen. We anticipate that large-scale studies with a longer follow-up period will further clarify the best treatment practices for wet-AMD patients.
